552 related articles for article (PubMed ID: 25954799)
1. Type 2 diabetes and metformin. First choice for monotherapy: weak evidence of efficacy but well-known and acceptable adverse effects.
Prescrire Int; 2014 Nov; 23(154):269-72. PubMed ID: 25954799
[TBL] [Abstract][Full Text] [Related]
2. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
3. Hypoglycaemic therapy in type 2 diabetes. Part I. Metformin is the only glucose-lowering drug known to prevent complications of diabetes.
Prescrire Int; 2015 Apr; 24(159):103-6. PubMed ID: 25941708
[TBL] [Abstract][Full Text] [Related]
4. Pioglitazone, rosiglitazone, and rosiglitazone + metformin: new drugs. Glitazone + oral antidiabetic combination: inadequately evaluated.
Prescrire Int; 2005 Aug; 14(78):133-9. PubMed ID: 16106595
[TBL] [Abstract][Full Text] [Related]
5. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Lancet; 1998 Sep; 352(9131):854-65. PubMed ID: 9742977
[TBL] [Abstract][Full Text] [Related]
6. Management of type 2 diabetes: long-awaited evidence of benefits after blood sugar control.
Prescrire Int; 1999 Oct; 8(43):147-52. PubMed ID: 11503841
[TBL] [Abstract][Full Text] [Related]
7. Metformin monotherapy for type 2 diabetes mellitus.
Saenz A; Fernandez-Esteban I; Mataix A; Ausejo M; Roque M; Moher D
Cochrane Database Syst Rev; 2005 Jul; (3):CD002966. PubMed ID: 16034881
[TBL] [Abstract][Full Text] [Related]
8. Metformin revisited: a critical review of the benefit-risk balance in at-risk patients with type 2 diabetes.
Scheen AJ; Paquot N
Diabetes Metab; 2013 May; 39(3):179-90. PubMed ID: 23528671
[TBL] [Abstract][Full Text] [Related]
9. Can people with type 2 diabetes live longer than those without? A comparison of mortality in people initiated with metformin or sulphonylurea monotherapy and matched, non-diabetic controls.
Bannister CA; Holden SE; Jenkins-Jones S; Morgan CL; Halcox JP; Schernthaner G; Mukherjee J; Currie CJ
Diabetes Obes Metab; 2014 Nov; 16(11):1165-73. PubMed ID: 25041462
[TBL] [Abstract][Full Text] [Related]
10. Metformin: diamonds are forever.
Papanas N; Maltezos E; Mikhailidis DP
Expert Opin Pharmacother; 2009 Oct; 10(15):2395-7. PubMed ID: 19678795
[TBL] [Abstract][Full Text] [Related]
11. Reduced cardiovascular morbidity and mortality associated with metformin use in subjects with Type 2 diabetes.
Johnson JA; Simpson SH; Toth EL; Majumdar SR
Diabet Med; 2005 Apr; 22(4):497-502. PubMed ID: 15787679
[TBL] [Abstract][Full Text] [Related]
12. A risk-benefit assessment of metformin in type 2 diabetes mellitus.
Howlett HC; Bailey CJ
Drug Saf; 1999 Jun; 20(6):489-503. PubMed ID: 10392666
[TBL] [Abstract][Full Text] [Related]
13. The effect of pioglitazone as add-on therapy to metformin or sulphonylurea compared to a fixed-dose combination of metformin and glibenclamide on diabetic dyslipidaemia.
Comaschi M; Corsi A; Di Pietro C; Bellatreccia A; Mariz S;
Nutr Metab Cardiovasc Dis; 2008 Jun; 18(5):373-9. PubMed ID: 17919894
[TBL] [Abstract][Full Text] [Related]
14. Glucose-lowering treatment of type 2 diabetes. Part II--Glucose-lowering drugs after metformin: a choice based largely on adverse effects.
Prescrire Int; 2015 May; 24(160):130-5. PubMed ID: 26034806
[TBL] [Abstract][Full Text] [Related]
15. Metformin. A review of its pharmacological properties and therapeutic use in non-insulin-dependent diabetes mellitus.
Dunn CJ; Peters DH
Drugs; 1995 May; 49(5):721-49. PubMed ID: 7601013
[TBL] [Abstract][Full Text] [Related]
16. Oral antihyperglycemic treatment options for type 2 diabetes mellitus.
Brietzke SA
Med Clin North Am; 2015 Jan; 99(1):87-106. PubMed ID: 25456645
[TBL] [Abstract][Full Text] [Related]
17. Increase in overall mortality risk in patients with type 2 diabetes receiving glipizide, glyburide or glimepiride monotherapy versus metformin: a retrospective analysis.
Pantalone KM; Kattan MW; Yu C; Wells BJ; Arrigain S; Jain A; Atreja A; Zimmerman RS
Diabetes Obes Metab; 2012 Sep; 14(9):803-9. PubMed ID: 22486923
[TBL] [Abstract][Full Text] [Related]
18. Metformin--the gold standard in type 2 diabetes: what does the evidence tell us?
Bosi E
Diabetes Obes Metab; 2009 May; 11 Suppl 2():3-8. PubMed ID: 19385978
[TBL] [Abstract][Full Text] [Related]
19. [New clinical data with metformin therapy in patients with diabetes mellitus].
Jermendy G
Orv Hetil; 2010 Dec; 151(49):2025-30. PubMed ID: 21106483
[TBL] [Abstract][Full Text] [Related]
20. [Proposal for the modification of metformin use in patients with chronic kidney disease].
Balogh Z; Mátyus J
Orv Hetil; 2012 Sep; 153(39):1527-35. PubMed ID: 23000419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]